Expert Opinion on Therapeutic Targets最新文献_第3页

IF 4.6 2区医学

Expert Opinion on Therapeutic Targets Pub Date : 2024-10-01 Epub Date: 2024-10-21 DOI: 10.1080/14728222.2024.2415014

Glykeria N Daneva, Panagiotis Tsiakanikas, Panagiotis G Adamopoulos, Andreas Scorilas

引用次数: 0

ULK1 as a therapeutic target in kidney diseases: Current perspective. 作为肾脏疾病治疗靶点的 ULK1：当前视角。

IF 4.6 2区医学

Expert Opinion on Therapeutic Targets Pub Date : 2024-10-01 Epub Date: 2024-11-11 DOI: 10.1080/14728222.2024.2421762

Shruti Shreya, Neha Dagar, Vishwadeep Shelke, Bhupendra Puri, Anil Bhanudas Gaikwad

{"title":"ULK1 as a therapeutic target in kidney diseases: Current perspective.","authors":"Shruti Shreya, Neha Dagar, Vishwadeep Shelke, Bhupendra Puri, Anil Bhanudas Gaikwad","doi":"10.1080/14728222.2024.2421762","DOIUrl":"10.1080/14728222.2024.2421762","url":null,"abstract":"Introduction: Globally, ~850 million people are affected by different kidney diseases. The pathogenesis of kidney diseases is intricate, where autophagy is crucial for maintaining kidney homeostasis. Iteliminates damaged organelles, thus reducing renal lesions and allowing tissue regeneration. Therefore, targeting various autophagy proteins, e.g. Unc-51-like autophagy-activating kinase 1 (ULK1), is emerging as potential therapeutic strategy against kidney disease.Areas covered: This review provides insights into the role of ULK1 as a therapeutic target in kidney diseases. Additionally, we have discussed the recent evidence based on pre-clinical studies for possible novel therapies modulating ULK1-mediated autophagy in kidney diseases.Expert opinion: ULK1 is one of the critical regulators of autophagy. Moreover, ULK1 works differently for different types of kidney disease. Considering its significant role in kidney disease pathogenesis, it could be a potential target to tackle kidney diseases. However, the dynamic molecular understanding of ULK1 in the context of various kidney diseases is still in its infancy and should be investigated further.","PeriodicalId":12185,"journal":{"name":"Expert Opinion on Therapeutic Targets","volume":" ","pages":"911-922"},"PeriodicalIF":4.6,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142617770","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Target potential of miRNAs in ulcerative colitis: what do we know? 溃疡性结肠炎中 MicroRNA 的靶标潜力：我们知道些什么？

IF 5.4 2区医学

Expert Opinion on Therapeutic Targets Pub Date : 2024-10-01 Epub Date: 2024-09-25 DOI: 10.1080/14728222.2024.2408423

Peeyush Kumar, Saurabh Kedia, Vineet Ahuja

{"title":"Target potential of miRNAs in ulcerative colitis: what do we know?","authors":"Peeyush Kumar, Saurabh Kedia, Vineet Ahuja","doi":"10.1080/14728222.2024.2408423","DOIUrl":"10.1080/14728222.2024.2408423","url":null,"abstract":"Introduction: The global rise in ulcerative colitis (UC) incidence highlights the urgent need for enhanced diagnostic and therapeutic strategies. Recent advances in genome-wide association studies (GWAS) have identified genetic loci associated with UC, providing insights into the disease's molecular mechanisms, including immune modulation, mucosal defense, and epithelial barrier function. Despite these findings, many GWAS signals are located in non-coding regions and are linked to low risk, suggesting that protein-coding genes alone do not fully explain UC's pathophysiology. Emerging research emphasizes the potential of microRNAs (miRNAs) as biomarkers and therapeutic targets due to their crucial role in UC. This review explores the current understanding of miRNAs in UC, including their mechanisms of action and their potential as both biomarkers and therapeutic targets. The present review provides the latest update on their potential as a biomarker and therapeutic target.Areas covered: This review synthesizes an extensive literature search on miRNAs in UC, focusing on their roles in the mucosal barrier, innate and adaptive immunity, and their potential applications as biomarkers and therapeutic modalities.Expert opinion: While miRNAs present promising opportunities as biomarkers and novel therapeutic agents in UC, challenges in validation, specificity, delivery, and clinical application need to be addressed through rigorous, large-scale studies.","PeriodicalId":12185,"journal":{"name":"Expert Opinion on Therapeutic Targets","volume":" ","pages":"829-841"},"PeriodicalIF":5.4,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142282691","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Progress and challenges in glypican-3 targeting for hepatocellular carcinoma therapy. 以 glypican-3 为靶点治疗肝细胞癌的进展与挑战。

IF 5.4 2区医学

Expert Opinion on Therapeutic Targets Pub Date : 2024-10-01 Epub Date: 2024-10-20 DOI: 10.1080/14728222.2024.2416975

Arnaud Couzinet, Toshihiro Suzuki, Tetsuya Nakatsura

{"title":"Progress and challenges in glypican-3 targeting for hepatocellular carcinoma therapy.","authors":"Arnaud Couzinet, Toshihiro Suzuki, Tetsuya Nakatsura","doi":"10.1080/14728222.2024.2416975","DOIUrl":"10.1080/14728222.2024.2416975","url":null,"abstract":"Introduction: Glypican-3 (GPC3) is a cell membrane-anchored heparan sulfate proteoglycan that has recently garnered attention as a cancer antigen owing to its high expression in numerous cancers, particularly hepatocellular carcinoma (HCC), and to limited expression in adult normal tissue.Areas covered: Here, we propose the potential of GPC3 as a cancer antigen based on our experience with the GPC3 peptide vaccine against HCC, having developed a vaccine that progressed from preclinical studies to first-in-human clinical trials. In this review, we present a summary of the current status and future prospects of immunotherapies targeting GPC3 by focusing on clinical trials; peptide vaccines, mRNA vaccines, antibody therapy, and chimeric antigen receptor/T-cell receptor - T-cell therapy and discuss additional strategies for effectively eliminating HCC through immunotherapy.Expert opinion: GPC3 is an ideal cancer antigen for HCC immunotherapy. In resectable HCC, immunotherapies that leverage physiological immune surveillance, immune checkpoint inhibitors, and GPC3-target cancer vaccines appear promising in preventing recurrence and could be considered as a prophylactic adjuvant therapy. However, in advanced HCC, clinical trials have not demonstrated sufficient anti-tumor efficacy, in contrast with preclinical studies. Reverse translation, bedside-to-bench research, is crucial to identify the factors that have hindered GPC3 target immunotherapies.","PeriodicalId":12185,"journal":{"name":"Expert Opinion on Therapeutic Targets","volume":" ","pages":"895-909"},"PeriodicalIF":5.4,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142461382","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

What is holding back preclinical GPR119 agonists from their potential as the therapeutics of type 2 diabetes? 是什么阻碍了临床前 GPR119 激动剂发挥治疗 2 型糖尿病的潜力？

IF 5.4 2区医学

Expert Opinion on Therapeutic Targets Pub Date : 2024-10-01 Epub Date: 2024-10-29 DOI: 10.1080/14728222.2024.2421751

Jing Hu, Yu Cao, Lianxiang Duan, Jinghua Peng

引用次数: 0

Targeting the TRPV1 pain pathway in osteoarthritis of the knee. 针对膝骨关节炎的 TRPV1 疼痛通路。

IF 5.4 2区医学

Expert Opinion on Therapeutic Targets Pub Date : 2024-10-01 Epub Date: 2024-10-25 DOI: 10.1080/14728222.2024.2416961

Ali Mobasheri, François Rannou, Stefan Ivanavicius, Philip G Conaghan

{"title":"Targeting the TRPV1 pain pathway in osteoarthritis of the knee.","authors":"Ali Mobasheri, François Rannou, Stefan Ivanavicius, Philip G Conaghan","doi":"10.1080/14728222.2024.2416961","DOIUrl":"10.1080/14728222.2024.2416961","url":null,"abstract":"Introduction: The growing prevalence and lack of effective pain therapies for knee osteoarthritis (KOA) results in a substantial unmet need for novel analgesic therapies. The transient receptor potential vanilloid 1 (TRPV1) receptor is expressed in subsets of nociceptive sensory neurons and has major roles in pain transmission and regulation. In the structures of the knee joint, nociceptors are present in abundance.Areas covered: TRPV1-expressing nociceptors in the knee represent a rational target to modulate activity at the origin of the pain pathway in KOA and may avoid systemic side effects seen with currently available analgesics. TRPV1 antagonists can induce analgesia, but hyperthermia and thermal hypesthesia side effects have limited their utility. Clinical development of TRPV1 agonists for pain management has progressed further than that of TRPV1 antagonists. Capsaicin and resiniferatoxin have provided proof-of-concept for the modulation of TRPV1 activity in KOA.Expert opinion: Intra-articular administration of TRPV1 agonists enables direct delivery to target nerve terminals in the knee, offering a potentially transformative approach for the management of pain associated with KOA. Here, we explore the advances in understanding innervation of the knee joint in KOA, the role of TRPV1-expressing neurons and progress in developing TRPV1 modulators for KOA.","PeriodicalId":12185,"journal":{"name":"Expert Opinion on Therapeutic Targets","volume":" ","pages":"843-856"},"PeriodicalIF":5.4,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142497723","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Expression of Concern: Overexpression of HMGA2 in breast cancer promotes cell proliferation, migration, invasion and stemness. 关注表达：乳腺癌中 HMGA2 的过表达会促进细胞增殖、迁移、侵袭和干性。

IF 5.4 2区医学

Expert Opinion on Therapeutic Targets Pub Date : 2024-10-01 Epub Date: 2024-10-21 DOI: 10.1080/14728222.2024.2417515

引用次数: 0

The role of Nrf2 in immune cells and inflammatory autoimmune diseases: a comprehensive review. Nrf2 在免疫细胞和炎症性自身免疫疾病中的作用：全面综述。

IF 5.8 2区医学

Expert Opinion on Therapeutic Targets Pub Date : 2024-09-10 DOI: 10.1080/14728222.2024.2401518

Wang-Dong Xu,Chan Yang,An-Fang Huang

{"title":"The role of Nrf2 in immune cells and inflammatory autoimmune diseases: a comprehensive review.","authors":"Wang-Dong Xu,Chan Yang,An-Fang Huang","doi":"10.1080/14728222.2024.2401518","DOIUrl":"https://doi.org/10.1080/14728222.2024.2401518","url":null,"abstract":"INTRODUCTIONNrf2 regulates mild stress, chronic inflammation, and metabolic changes by regulating different immune cells via downstream signaling. Collection of information about the role of Nrf2 in inflammatory autoimmune diseases will better understand the therapeutic potential of targeting Nrf2 in these diseases.AREAS COVEREDIn this review, we comprehensively discussed biological function of Nrf2 in different immune cells, including Nrf2 preventing oxidative tissue injury, affecting apoptosis of immune cells and inflammatory cytokine production. Moreover, we discussed the role of Nrf2 in the development of inflammatory autoimmune diseases.EXPERT OPINIONNrf2 binds to downstream signaling molecules and then provides durable protection against different cellular and organ stress. It has emerged as an important target for inflammatory autoimmune diseases. Development of Nrf2 modulator drugs needs to consider factors such as target specificity, short/long term safety, disease indication identification, and the extent of variation in Nrf2 activity. We carefully discussed the dual role of Nrf2 in some diseases, which helps to better target Nrf2 in the future.","PeriodicalId":12185,"journal":{"name":"Expert Opinion on Therapeutic Targets","volume":"12 1","pages":"1-18"},"PeriodicalIF":5.8,"publicationDate":"2024-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142178925","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Can we target insulin signalling for cognition therapeutics? 我们能否针对胰岛素信号进行认知治疗？

IF 4.6 2区医学

Expert Opinion on Therapeutic Targets Pub Date : 2024-09-01 Epub Date: 2024-09-24 DOI: 10.1080/14728222.2024.2407821

Simone Macrì, Giovanni Laviola

引用次数: 0

Combined cancer immunotherapy based on targeting adenosine pathway and PD-1/PDL-1 axis. 以腺苷通路和 PD-1/PDL-1 轴为靶点的联合癌症免疫疗法。

IF 4.6 2区医学

Expert Opinion on Therapeutic Targets Pub Date : 2024-09-01 Epub Date: 2024-09-20 DOI: 10.1080/14728222.2024.2405090

Mehrdad Fathi, Asieh Zarei, Ata Moghimi, Pooya Jalali, Zahra Salehi, Sharareh Gholamin, Farhad Jadidi-Niaragh

{"title":"Combined cancer immunotherapy based on targeting adenosine pathway and PD-1/PDL-1 axis.","authors":"Mehrdad Fathi, Asieh Zarei, Ata Moghimi, Pooya Jalali, Zahra Salehi, Sharareh Gholamin, Farhad Jadidi-Niaragh","doi":"10.1080/14728222.2024.2405090","DOIUrl":"10.1080/14728222.2024.2405090","url":null,"abstract":"Introduction: Cancer immunotherapy has revolutionized the field of oncology, offering new hope to patients with advanced malignancies. Tumor-induced immunosuppression limits the effectiveness of current immunotherapeutic strategies, such as PD-1/PDL-1 checkpoint inhibitors. Adenosine, a purine nucleoside molecule, is crucial to this immunosuppression because it stops T cells from activating and helps regulatory T cells grow. Targeting the adenosine pathway and blocking PD-1/PDL-1 is a potential way to boost the immune system's response to tumors.Areas covered: This review discusses the current understanding of the adenosine pathway in tumor immunology and the preclinical and clinical data supporting the combination of adenosine pathway inhibitors with PD-1/PDL-1 blockade. We also discuss the challenges and future directions for developing combination immunotherapy targeting the adenosine pathway and the PD-1/PDL-1 axis for cancer treatment.Expert opinion: The fact that the adenosine signaling pathway controls many immune system processes suggests that it has a wide range of therapeutic uses. Within the next five years, there will be tremendous progress in this area, and the standard of care for treating malignant tumors will have switched from point-to-point therapy to the integration of immunological networks comprised of multiple signaling pathways, like the adenosine axis.","PeriodicalId":12185,"journal":{"name":"Expert Opinion on Therapeutic Targets","volume":" ","pages":"757-777"},"PeriodicalIF":4.6,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142282689","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0